MedTrace Logo

[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers

NCT04320030 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2023-02-21

No results posted yet for this study

Summary

This phase II study is assessing the correlation between M1/M2 macrophage polarization determined by tumor immunohistochemistry analysis and \[18F\]DPA-714 PET/CT binding (qualitative and texture analysis) in patients with operable triple negative breast cancer.

Conditions

Interventions

DRUG

[18F]-DPA-714 PET/CT scan

Pretherapeutic \[18F\]-DPA-714 PET/CT scan

Sponsors & Collaborators

  • SIRIC ILIAD

    collaborator UNKNOWN

  • Institut Cancerologie de l'Ouest

    lead OTHER

Principal Investigators

  • Caroline ROUSSEAU, MD, PhD · Institut de Cancerologie de l'Ouest

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-11
Primary Completion
2021-07-21
Completion
2021-07-21

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04320030 on ClinicalTrials.gov